Neuroinflammatory signals in alzheimer disease and APP/PS1 transgenic mice: Correlations with plaques, tangles, and oligomeric species

Journal of Neuropathology and Experimental Neurology

Volumn 74, Issue 4, 2015, Pages 319-344

  López González, Irene ^a   Schlüter, Agatha ^a,e   Aso, Ester ^a   Garcia Esparcia, Paula ^a   Ansoleaga, Belen ^a   Llorens, Franc ^a   Carmona, Margarita ^a   Moreno, Jesús ^a   Fuso, Andrea ^g,h   Portero Otin, Manuel ^f   Pamplona, Reinald ^f   Pujol, Aurora ^a,c,e   Ferrer, Isidre ^a,b,d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^f UNIVERSITY OF LLEIDA   (Spain)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Beta amyloid; Cytokines; Genomics; Neuroinflammation; Sporadic Alzheimer disease; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CYTOKINE; MESSENGER RNA; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AUTACOID; PEPTIDE FRAGMENT; PRESENILIN 1;

ADULT; AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; ENTORHINAL CORTEX; FEMALE; FRONTAL CORTEX; FUNCTIONAL GENOMICS; GENE; GENE CONTROL; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; MICROGLIA; MIDDLE AGED; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; ORBITAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RNA ANALYSIS; SPECIES DIFFERENCE; AGED; AMYLOID PLAQUE; ANIMAL; BIOSYNTHESIS; GENETICS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CEREBRAL CORTEX; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; NEUROFIBRILLARY TANGLES; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; PRESENILIN-1;

EID: 84925867468     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000176     Document Type: Article

References (132)

1. Duyckaerts C, Dickson D. Neuropathology of Alzheimer's disease and its variants. In: Dickson D, Weller R, eds. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, 2nd ed. West Sussex, England: Wiley-Blackwell, 2011:62-91
2. Bertram L, Tanzi RE. Genetics of Alzheimer's disease. In: Dickson D, Weller R, eds. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, 2nd ed. West Sussex, England: Wiley-Blackwell, 2011:51-61
3. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
4. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351-57
5. Braak H, Braak E. Temporal sequence of Alzheimer's diseaseYrelated pathology. In: Peters A, Morrison JH, eds. Cerebral Cortex: Neurodegenerative and Age-Related Changes in Structure and Function of Cerebral Cortex, vol. 14. New York, NY: Kluwer Academic/Plenum Publishers, 1999:475-512
6. Braak H, Thal DR, Ghebremedhin E, del Tredici K. Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011;70:960-69
7. Grinberg LT, Rb U, Ferretti RE, Nitrini R, Farfel JM, Polichiso L; Brazilian Brain Bank Study Group. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset?. Neuropathol Appl Neurobiol 2009;35:406-16
8. Thal DR, Rüb U, Orantes M, Braak H. Phases of AA-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-800
9. Markesbery WR. Neuropathologic alterations in mild cognitive impairment: A review. J Alzheimers Dis 2010;19:221-28
10. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol 2012;71:362-81
11. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of non-demented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30:1026-36
12. Ohm TG, Müller H, Braak H, Bohl J. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's diseaseYrelated neurofibrillary changes. Neuroscience 1995;64:209-17
13. Ferrer I. Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog Neurobiol 2012; 97:38-51
14. McGeer PL, McGeer EG. The amyloid cascadeVinflammatory hypothesis of Alzheimer disease: Implications for therapy. Acta Neuropathol 2013;126:479-97
15. Selkoe DJ. Preventing Alzheimer's disease. Science 2012;337:1488-92
16. Ferrer I. Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. J Bioenerg Biomembr 2009;41:425-31
17. Pamplona R, Dalfó E, Ayala V, et al. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation: Effects of Alzheimer disease and identification of lipoxidation targets. Mol J Biol Chem 2005;1280:21522-30
18. Sultana R, Butterfield DA. Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis 2010;19:341-53
19. Martýn V, Fabelo N, Santpere G, et al. Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J Alzheimers Dis 2010; 19:489-502
20. Cataldo AM, Paskevich PA, Kominami E, Nixon RA. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proc Natl Acad Sci U S A 1991;88:10998-1002
21. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem 2000;75:436-39
22. Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol 2014;14:463-77
23. Mc Geer PL, McGeer EG. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995;21:195-218
24. McGeer PL, McGeer EG. History of innate immunity in neurodegenerative disorders. Front Pharmacol 2011;2:77
25. Moore AH, O'Banion MK. Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv Drug Deliv Rev 2002;54:1627-56
26. Prokop S, Miller KR, Heppner FL. Microglia actions in Alzheimer's disease. Acta Neuropathol 2013;126:461-77
27. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease. Am J Psychiatry 1994;151:1105-13
28. Iqbal K, Coleman PD (eds). The Fifth International Conference on Alzheimer's Disease and related Disorders. Neurobiol Aging 1996; 17,suppl 1:S1YS213
29. Roggers J, Griffin WST. Inflammatory mechanisms of Alzheimer's disease. In: Wood PL, ed. Neuroinflammation: Mechanisms and Management. Totowa, NY: Humana Press, 1998:177-93
30. Arends YM, Duyckaerts C, Rozemuller JM, et al. Microglia, amyloid and dementia in Alzheimer's disease. A correlative study. Neurobiol Aging 2000;21:39-47
31. Bamberger ME, Harris ME, McDonald DR, et al. A cell surface receptor complex for fibrillary-amyloid mediates microglial activation. J Neurosci 2003;23:2665-74
32. McGeer PL, McGeer EG. Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci 2004;1035:104-16
33. Weller RO, Subash M, Preston SD, et al. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008;18:253-66
34. Mandrekar S, Jiang Q, Lee CY, et al. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci 2009; 29:4252-62
35. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421
36. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Arch Pharm Res 2010;33:1539-56
37. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 2001;22:799-809
38. Rubio-Perez JM, Morillas-Ruiz JM. A review: Inflammatory process in Alzheimer's disease, role of cytokines. Sci World J 2012;2012:56357
39. Streit WJ, Conde JR, Harrison JK. Chemokines and Alzheimer's disease. Neurobiol Aging 2001;22:909-13
40. Matsuoka Y, Picciano M, Malester B, et al. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol 2001;158:1345-54
41. Wirz KTS, Bossers K, Stargardt A, et al. Cortical beta-amyloid protein triggers an immune response, but not synaptic changes in the APPswe/PS1dE9 Alzheimer's disease mouse model. Neurobiol Aging 2013:34:1328-42
42. Griffin WS, Sheng JG, Royston MC, et al. . Glial-neuronal interactions in Alzheimer's disease: The potential role of a 'cytokine cycle' in disease progression. Brain Pathol 1998;8:65-72
43. Leung E, Guo L, Bu J, et al. Microglia activation mediates fibrillar amyloid-beta toxicity in the aged primate cortex. Neurobiol Aging 2011;32:387-97
44. Streit WJ, Greber MB, Kreutzberg GW. Functional plasticity of microglia: A review. Glia 1988;1:301-7
45. Kreutzberg GW. Microglia: A sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-18
46. Streit W. Microglia and neuroprotection: Implications for Alzheimer's disease. Brain Res Rev 2005;48:234-39
47. Graeber MB, Streit WJ. Microglia: Biology and pathology. Acta Neuropathol 2010;119:89-105
48. Graeber MB, Li W, Michael L, Rodríguez ML. Role of microglia in CNS inflammation. FEBS Lett 2011;585:3798-805
49. Morimoto K, Horio J, Satoh H, et al. Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients, compared to the brains of non-demented patients with and without increasing AD pathology. J Alzheimers Dis 2011;25:59-76
50. Streit WJ, Samkons NW, Kuhns AJ, Sparks DL. Dystrophic microglia in the aging human brain. Glia 2004;45:208-12
51. Streit WJ, Braak H, Xue QS, et al. Dystrophic (senescent) rather than activated microglial cells are associated tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 2009; 118:475-85
52. Fernández PL, Britton GB, Rao KS. Potential immunotargets of Alzheimer's disease treatment strategies. J Alzheimers Dis 2013;33: 297-312
53. McGeer EG, McGeer PL. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: A field in its infancy. J Alzheimers Dis 2010;19:355-61
54. Li C, Ebrahimi A, Schluesener H. Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease. Ageing Res Rev 2013;12:116-40
55. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's diseaseYlinked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996;17:1005-13
56. Aso E, Lomoio S, López-González I, et al. Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease. Brain Pathol 2012;22: 636-53
57. Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer diseaseYassociated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389-404
58. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80
59. Smyth GK. Machine learning concepts and tools for statistical genomics. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, eds. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York, NY: Springer, 2005:397-420
60. Schlüter A, Espinosa L, Fourcade S, et al. Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy. Hum Mol Genet 2012;21:1062-77
61. Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007;23:257-58
62. Mootha VK, Bunkenborg J, Olsen JV, et al. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell 2003;115:629-40
63. Barrachina M, Castaño E, Ferrer I. TaqMan PCR assay in the control of RNA normalization in human post-mortem brain tissue. Neurochem Int 2006;49:276-84
64. Durrenberg PF, Fernando S, Kashefi SN, et al. Selection of novel reference genes for use in the human central nervous system: A BrainNet Study. Acta Neuropathol 2012;124:893-903
65. Michaud M, Balardy L, Moulis G, et al. Pro-inflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc 2013;14:877-82
66. Pizza V, Agresta A, D'Acunto CW, FestaM, Capasso A. Neuroinflammation and ageing: Current theories and an overview of the data. Rev Recent Clin Trials 2011;6:189-203
67. Godbout JP, Johnson RW. Age and neuroinflammation: A lifetime of psychoneuroimmune consequences. Neurol Clin 2006;24:521-38
68. Bodles AM, Barger SW. Cytokines and the aging brainVwhat we don't know might help us. Trends Neurosci 2004;27:621-26
69. Holmes C. Review: Systemic inflammation and Alzheimer's disease. Neuropathol Appl Neurobiol 2013;39:51-68
70. Ownby RL. Neuroinflammation and cognitive aging. Curr Psychiatry Rep 2010;12:39-45
71. Perry VH. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol 2010;120:277-86
72. Sardi F, Fassina L, Venturini L, et al. Alzheimer's disease, autoimmunity and inflammation: The good, the bad and the ugly. Autoimmun Rev 2011;11:149-53
73. Jimenez S, Baglietto-Vargas D, Caballero C, et al. Inflammatory response in the hippocampus of mouse model of Alzheimer's disease: Age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci 2008;28:1650-61
74. Hardy J. The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. J Neurochem 2009;110:1129-34
75. Katsuno T, Morishima-Kawashima M, Saito Y, et al. Independent accumulations of tau and amyloid-beta protein in the human entorhinal cortex. Neurology 2005;64:687-82
76. Delacourte A. The natural and molecular history of Alzheimer's disease. J Alzheimers Dis 2006;9:187-84
77. Hurtado DE, Molina-Porcel L, Iba M, et al. AA accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol 2010;177:1977-88
78. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001;293:1487-91
79. Masters CL, Beyreuther K. Alzheimer's centennial legacy: Prospects for rational therapeutic intervention targeting the AA amyloid pathway. Brain 2006;129:2823-39
80. Tomiyama T, Matsuyama S, Iso H, et al. A mouse model of amyloid beta oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 2010;30:4845-56
81. Medeiros R, LaFerla FM. Astrocytes: Conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol 2013;239:133-38
82. Ferretti MT, Cuello AC. Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment?. Curr Alzheimer Res 2011;8:164-74
83. Yu D, Corbett B, Yan Y, et al. Early cerebrovascular inflammation in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 2012; 33:2942-47
84. Rijal-Upadhaya A, Capetillo-Zarate E, Kosterin I, et al. Dispersible amyloid A-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: Their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice. Neurobiol Aging 2012; 33:2641-60
85. Rijal-Upadhaya A, Kosterin I, Kumar S, et al. Biochemical stages of amyloid-A peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. Brain 2014;137:887-903
86. Haass J, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-2
87. Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem 2008;283:29639-43
88. Glabe CG. Amyloid oligomer structures and toxicity. Open Biol J 2009; 2:222-27
89. Shankar GM, Li S, Mehta TH, et al. Amyloid A-protein dimers isolated directly from Alzheimer brains impair synaptic plasticity and memory. Nat Med 2008;14:837-42
90. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB. Amyloid A-protein assembly and Alzheimer disease. J Biol Chem 2009;284:4749-53
91. Benilova I, Karran T, De Strooper B. The toxic AA oligomer and Alzheimer's disease: An emperor in need of clothes. Nat Neurosci 2012; 15:349-57
92. Mucke L, Selkoe DJ. Neurotoxicity of amyloid A-protein: Synaptic and network dysfunction. Cold Spring Harb Perspect Med 2012;2:a006338
93. Zhao LN, Long HW, Mu Y, Chew LY. The toxicity of amyloid A oligomers. Int J Mol Sci 2012;13:7303-27
94. Kayed R, Lasagna-Reeves AL. Molecular mechanisms of amyloid oligomers toxicity. J Alzheimers Dis 2013;33:S67-78
95. Prelli F, Castaño E, Glenner GG, Frangione B. Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem 1988;51:648-51
96. Miller DL, Papayannopoulos IA, Styles J, et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 1993;301:41-52
97. Roher AE, Lowenson JD, Clarke S, et al. A-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease. Proc Natl Acad Sci U S A 1993;90: 10836-40
98. Näslund J, Schierhorn A, Hellman U, et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A 1994;91:8378-82
99. Saido TC, Iwatsubo T, Mann DM, et al. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995;14:457-66
100. Lewis H, Beher D, Cookson N, et al. Quantification of Alzheimer pathology in ageing and dementia: Age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol Appl Neurobiol 2006;32:103-18
101. Portelius E, Bogdanovic N, Gustavsson MK, et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol 2010;120:185-93
102. Saito T, Suemoto T, Brouwers N, et al. Potent amyloidogenicity and pathogenicity of AA43. Nat Neurosci 2011;14:1023-32
103. Jawhar S, Wirths O, Bayer TA. Pyroglutamate amyloid-A (AA): A hatched man in Alzheimer disease. J Biol Chem 2011;286:38825-27
104. Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 2009;35:352-58
105. Arshavsky YI. Alzheimer disease and cellular mechanisms of memory storage. J Neuropathol Exp Neurol 2014;73:192-205
106. Graeber MB. Changing face of microglia. Science 2010;330:783-88
107. Paolicelli RC, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for normal brain development. Science 2011;333:1456-58
108. Schafer DP, Lehrman EK, Kautzman AG, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012;74:691-705
109. Parkhurst CN, Yang G, Ninan I, et al. Microglia promote learningdependent synapse formation through brain-derived neurotrophic factor. Cell 2013;155:1596-609
110. Zhan Y, Paolicelli RC, Sforazzini F, et al. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci 2014;17:400-6
111. Estes ML, McAllister AK. Alterations in immune cells and mediators in the brain: It's not always neuroinflammation Brain Pathol 2014;24: 623-30
112. Svahn AJ, Becker TS, Graeber MB. Emergent properties of microglia. Brain Pathol 2014;24:665-70
113. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000;20:5709-14
114. Jantzen PT, Connor KE, DiCarlo G, et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxideYreleasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 2002;22:2246-54
115. van Groen T, Miettinen P, Kadish I. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation, and pathology. J Alzheimers Dis 2011;24:301-13
116. Bachstetter AD, Norris CM, Sompol P, et al. Early stage drug treatment that normalizes pro-inflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's diseaseYrelated pathology. J Neurosci 2012;32: 10201-10
117. Gabbita SP, Srivastava MK, Eslami P, et al. Early intervention with a small molecule inhibitor for tumor necrosis factor-> prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. J Neuroinflammation 2012;9:99
118. Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol 2002;1:937-44
119. Reines SA, Block GA, Morris JC, et al. Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62:66-71
120. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006;1:e33
121. Soininen H, West C, Robbins J, et al. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 23:8-21
122. Jaturapatporn D, Isaac MG, McCleery J, et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012;2:CD006378
123. Shi S, Wang Z, Qiao Z. The multifunctional anti-inflammatory drugs used in the therapy of Alzheimer's disease. Curr Med Chem 2013;20: 2583-88
124. Streit WJ. Microglial senescence: Does the brain's immune system have an expiration date?. Trends Neurosci 2006;29:506-10
125. Mackenzie IRA, Muñoz DG. Non-steroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 1998;50:986-90
126. Jenkinson ML, Bliss MR, Brain AT, Scott DL. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol 1989;28:86-88
127. McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990;335:1037
128. Myllykangas-Luosujarvi R, Isomaki H. Alzheimer's disease and rheumatoid arthritis. Br J Rheumatol 1994;33:501-2
129. Breitner JC, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with non-steroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995;16:523-30
130. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-32
131. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008;70: 1672-77
132. Zandi PP, Anthony JC, Hayden KM, et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study. Neurology 2002;59:880-86